

Special Issue

Endocrine and Neuroendocrine Cancers

Message from the Guest Editors

Endocrine and neuroendocrine tumors represent heterogeneous diseases that have an endocrine cell onset as a common denominator. Many of these neoplasms are relatively rare and may be included in genetic syndromes. Their treatment is often challenging and requires a multidisciplinary approach. In recent years, we have witnessed an improvement in the biological and pathogenetic knowledge of these diseases, and new effective drugs have been identified. This Special Issue will focus on the current state of the art and future prospects in a) diagnosis, b) genetics, c) biology and genomics, d) multidisciplinary approaches and the effectiveness of currently available therapies, and e) new molecular targeted therapies and immunotherapies.

Guest Editors

Prof. Dr. Alfredo Berruti

Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia at ASST Spedali Civili di Brescia, 25124 Brescia, Italy

Dr. Vito Amoroso

Medical Oncology Unit, ASST-Spedali Civili, Brescia, Italy

Dr. Nicola Fazio

Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy

Deadline for manuscript submissions

closed (30 November 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/58921

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)